Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders

Bibliography

• Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109(9):1705-14
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002;136-61
   PubMedGoogle Scholar
• Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012;120(10):2076-86
   PubMed Web of Science ®Google Scholar
• Pang WW, Pluvinage JV, Price EA, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci USA 2013;110(8):3011-16
   PubMed Web of Science ®Google Scholar
• Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82(2):358-67
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45-52
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109(8):1536-42
   PubMed Web of Science ®Google Scholar
• Doll DC, List AF. Myelodysplastic syndromes. Western J Med 1989;151(2):161-7
   PubMedGoogle Scholar
• Hofmann WK, Ottmann OG, Ganser A, Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol 1996;33(3):177-85
   PubMed Web of Science ®Google Scholar
• Foucar K, Langdon RM II, Armitage JO, et al. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 1985;56(3):553-61
   PubMed Web of Science ®Google Scholar
• Konstantopoulos K, Lauren L, Hast R, Reizenstein P. Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome. Anticancer Res 1989;9(4):893-6
   PubMed Web of Science ®Google Scholar
• Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368(9550):1894-907
   PubMed Web of Science ®Google Scholar
• Kuter DJ. What is the potential for thrombopoietic agents in acute leukemia? Best Pract Res Clin Haematol 2011;24(4):553-8
   PubMed Web of Science ®Google Scholar
• Gupta P, LeRoy SC, Luikart SD, et al. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999;23(10):953-9
   PubMed Web of Science ®Google Scholar
• Sepulveda JL, Oren E. Alloimmunization from transfusions. WebMD, Inc. Available from: www.emedicine.com/med/topic107.htm; 2008
   Google Scholar
• Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994;369(6481):565-8
   PubMed Web of Science ®Google Scholar
• Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77(7):1117-24
   PubMed Web of Science ®Google Scholar
• de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369(6481):533-8
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100(10):3457-69
   PubMed Web of Science ®Google Scholar
• Sattler M, Durstin MA, Frank DA, et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol 1995;23(9):1040-8
   PubMed Web of Science ®Google Scholar
• Yamada M, Komatsu N, Kirito K, et al. Thrombopoietin supports in vitro erythroid differentiation via its specific receptor c-Mpl in a human leukemia cell line. Cell Growth Differ 1998;9(6):487-96
   PubMedGoogle Scholar
• Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999;94(1):365-7
   PubMed Web of Science ®Google Scholar
• Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 2002;21(21):3359-67
   PubMed Web of Science ®Google Scholar
• Luengo JI, Duffy KJ, Shaw AN, et al. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood 2004;104(11):2910-0
   Google Scholar
• Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91(23):11104-8
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Clin Lymphoma Myeloma 2009;9(Suppl 3):S347-56
   PubMedGoogle Scholar
• Schuster MW, Beveridge R, Frei-Lahr D, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002;30(9):1044-50
   PubMed Web of Science ®Google Scholar
• Bolwell B, Vredenburgh J, Overmoyer B, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000;26(2):141-5
   PubMed Web of Science ®Google Scholar
• Nash RA, Kurzrock R, DiPersio J, et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000;6(1):25-34
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98(12):3241-8
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells (Dayton, Ohio) 2009;27(2):424-30
   PubMed Web of Science ®Google Scholar
• Erickson-Miller C, Delorme E, Giampa L, et al. Biological activity and selectivity for Tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. ASH Annual Meeting Abstracts 2004;104(11):2912
   Google Scholar
• Erickson-Miller C, Tian S-S, Hopson C, et al. Species specificity and receptor domain interaction of a small molecule Tpo receptor agonist, SB-497115. AACR Meeting Abstracts 2005;2005(1):1163-4
   Google Scholar
• Erhardt JA, Erickson-Miller CL, Aivado M, et al. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009;37(9):1030-7
   PubMed Web of Science ®Google Scholar
• Haselboeck J, Pabinger I, Ay C, et al. Platelet activation and function during eltrombopag treatment in immune thrombocytopenia. Ann Hematol 2012;91(1):109-13
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357(22):2237-47
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357(22):2227-36
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373(9664):641-8
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377(9763):393-402
   PubMed Web of Science ®Google Scholar
• Afdhal N, Dusheiko G, Giannini EG, et al. Final results of ENABLE 1, a phase 3, multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus-related chronic liver disease associated with thrombocytopenia. Hepatology 2011;54(S1):100A
   Google Scholar
• Dusheiko G, Afdhal N, Giannini E, et al. 60 Results of enable 2, a phase 3, multicenter study of eltrombopag and peginterferon alfa-2B treatment in patients with hepatitis C and thrombocytopenia. J Hepatol 2012;56:S27
   Web of Science ®Google Scholar
• Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012;367(8):716-24
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012;367(1):11-19
   PubMed Web of Science ®Google Scholar
• Takeshita A, Shinjo K, Izumi M, et al. Quantitative expression of thrombopoietin receptor on leukaemia cells from patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. Br J Haematol 1998;100(2):283-90
   PubMed Web of Science ®Google Scholar
• Vigon I, Dreyfus F, Melle J, et al. Expression of the c-mpl proto-oncogene in human hematologic malignancies. Blood 1993;82(3):877-83
   PubMed Web of Science ®Google Scholar
• Schroder JK, Kolkenbrock S, Tins J, et al. Analysis of thrombopoietin receptor (c-mpl) mRNA expression in de novo acute myeloid leukemia. Leuk Res 2000;24(5):401-9
   PubMed Web of Science ®Google Scholar
• Luo SS, Ogata K, Yokose N, et al. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. Stem Cells (Dayton, Ohio) 2000;18(2):112-19
   PubMed Web of Science ®Google Scholar
• Kalina U, Hofmann WK, Koschmieder S, et al. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Exp Hematol 2000;28(10):1158-63
   PubMed Web of Science ®Google Scholar
• Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009;114(18):3899-908
   PubMed Web of Science ®Google Scholar
• Kalota A, Gewirtz AM. A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. Blood 2010;115(1):89-93
   PubMed Web of Science ®Google Scholar
• Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 2012;120(2):386-94
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Kirchner J, Aivado M, et al. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010;34(9):1224-31
   PubMed Web of Science ®Google Scholar
• Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res 2011;35(3):323-8
   PubMed Web of Science ®Google Scholar
• Sugita M, Kalota A, Gewirtz AM, Carroll M. Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression. Leukemia 2013;27;5:1207-10
   Google Scholar
• Hoyes KP, Hider RC, Porter JB. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res 1992;52(17):4591-9
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Pillarisetti K, Kirchner J, et al. Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors. BMC Cancer 2012;12:405
   PubMedGoogle Scholar
• Hoffbrand AV, Ganeshaguru K, Hooton JW, Tattersall MH. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976;33(4):517-26
   PubMed Web of Science ®Google Scholar
• Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet 1980;2(8191):390-2
   PubMed Web of Science ®Google Scholar
• Seymour GJ, Walsh MD, Lavin MF, et al. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 1987;15(6):341-4
   PubMed Web of Science ®Google Scholar
• Cavanaugh PG, Jia L, Zou Y, Nicolson GL. Transferrin receptor overexpression enhances transferrin responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line. Breast Cancer Res Treat 1999;56(3):203-17
   PubMed Web of Science ®Google Scholar
• Bergeron RJ, Cavanaugh PF Jr, Kline SJ, et al. Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators. Biochem Biophys Res Commun 1984;121(3):848-54
   PubMed Web of Science ®Google Scholar
• Seligman PA, Schleicher RB, Siriwardana G, et al. Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation. Blood 1993;82(5):1608-17
   PubMed Web of Science ®Google Scholar
• Torti SV, Torti FM, Whitman SP, et al. Tumor cell cytotoxicity of a novel metal chelator. Blood 1998;92(4):1384-9
   PubMed Web of Science ®Google Scholar
• Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem 2002;45(17):3573-5
   PubMed Web of Science ®Google Scholar
• Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of Naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem 2002;45(17):3576-8
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Mufti GJ, Fenaux P, et al. Treatment with the thrombopoietin (tpo)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): Follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study. 54th ASH Annual Meeting and Exposition; 2012
   Google Scholar
• Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109(11):4739-41
   PubMed Web of Science ®Google Scholar